Orphazyme no longer expects EMA decision this year

Orphazyme will likely have to wait until sometime during the first quarter of 2022 to receive a decision from the European Medicines Agency on its key candidate arimoclomol as a treatment for Niemann-Pick disease type C, the company reports.

Photo: Orphazyme/PR

Biotech company Orphazyme, which is based in Copenhagen, Denmark, must arm itself with more patience.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs